Hua Medicine (Shanghai) Ltd.

HKSE 2552.HK

Hua Medicine (Shanghai) Ltd. EBT Margin for the year ending December 31, 2023: -275.73%

Hua Medicine (Shanghai) Ltd. EBT Margin is -275.73% for the year ending December 31, 2023, a 76.16% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Hua Medicine (Shanghai) Ltd. EBT Margin for the year ending December 31, 2022 was -1,156.36%.
Hua Medicine (Shanghai) Ltd. EBT Margin for the year ending December 31, 2020 was -4,537.56%, a -137.48% change year over year.
Hua Medicine (Shanghai) Ltd. EBT Margin for the year ending December 31, 2019 was -1,910.72%, a 95.16% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

HKSE: 2552.HK

Hua Medicine (Shanghai) Ltd.

CEO	Dr. Li Chen Ph.D.
IPO Date	Sept. 14, 2018
Location	China
Headquarters	Building A
Employees	172
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Key trends

Past 5 years